Subgroup analysis of Phase 3 trial (PUNCH™ CD3) looked at health-related quality of life data in patients treated with RBX2660…
Findings from the analysis underscore Ferring’s commitment to identifying and addressing the needs of healthcare professionals and fertility clinic staff…
Created in partnership with Robyn, a community-driven digital platform, Fertility Outreach evolves the fertility journey by providing a text-based solution…
Parsippany, NJ – October 11, 2022 – Ferring Pharmaceuticals today announced it will present data from new analyses of RBX2660, an…
Parsippany, NJ – October 6, 2022 – Ferring Pharmaceuticals today announced they will present analyses of RBX2660, an investigational microbiota-based live…
Vaccines and Related Biological Products Advisory Committee reviewed data from the biologics license application for RBX2660 RBX2660 is an investigational…
Ferring to share insights and expertise across a range of timely and critical topics at the Women’s Health Innovation Summit…
Vaccines and Related Biological Products Advisory Committee will hold meeting on September 22, 2022 RBX2660 is an investigational microbiota-based live…
New subgroup analyses presented at Digestive Disease Week® (DDW) 2022 on the integrated efficacy results of Phase 2b and Phase…
Parsippany, NJ – May 11, 2022 – Ferring Pharmaceuticals today announced they will present data from analyses of RBX2660, an…